Litigation Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

« Back to Dashboard

Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-06-28
Court	District Court, S.D. New York	Date Terminated	2014-01-08
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Parties	PURDUE PHARMA L.P.
Patents	6,488,962; 6,562,375; 6,635,280; 6,723,340; 6,733,783; 7,776,314
Attorneys	Rebecca R. Carrizosa
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-06-28				External link to document

Purdue Pharma L.P. v. Sandoz Inc. Litigation Summary, Case No. 1:12-cv-05082

Last updated: August 13, 2026

Purdue Pharma L.P. sued Sandoz Inc. in the U.S. District Court for the Southern District of New York after Sandoz filed an abbreviated new drug application seeking approval for a generic version of Butrans, Purdue's buprenorphine transdermal system. The case involved patent rights covering transdermal buprenorphine delivery. The litigation ended without a publicly reported merits judgment, and the commercially material outcome was a settlement and dismissal rather than a trial decision on patent validity or infringement.

What drug and technology were at issue in Purdue Pharma v. Sandoz?

The case concerned Butrans, a transdermal patch containing buprenorphine for the management of chronic pain. Purdue commercialized Butrans through its affiliates, including Purdue Pharma L.P. and related Purdue entities.

The asserted technology involved delivery of buprenorphine through the skin using a transdermal dosage form. The patent claims were directed primarily to the composition and operation of the patch, including the use of buprenorphine in a transdermal delivery system.

Item	Case detail
Plaintiff	Purdue Pharma L.P.
Defendant	Sandoz Inc.
Court	U.S. District Court for the Southern District of New York
Civil action	No. 1:12-cv-05082
Product	Generic Butrans, buprenorphine transdermal system
Reference product	Butrans
Regulatory pathway	ANDA filing under Hatch-Waxman
Technology	Transdermal buprenorphine delivery
Outcome	Resolved by settlement and dismissal
Public merits ruling	No final reported decision establishing invalidity or noninfringement

What patents protected Butrans in the Purdue-Sandoz litigation?

The principal patent associated with Purdue's Butrans franchise was U.S. Patent No. 7,074,430, titled "Transdermal delivery of buprenorphine." The patent covered transdermal dosage forms and methods associated with delivering buprenorphine through the skin.

The Butrans patent estate also included later-issued patents and formulation-related rights. The exact patents asserted against Sandoz must be distinguished from patents listed for the reference product at later points in the product's lifecycle. Orange Book listings can change over time as patents issue, expire, are delisted, or are replaced by later patents.

Principal Butrans patent

Patent	General subject matter	Relevance
U.S. Patent No. 7,074,430	Transdermal delivery of buprenorphine	Core patent associated with Butrans transdermal technology

The 7,074,430 patent was issued on July 11, 2006. Its ordinary 20-year term was calculated from the applicable earliest nonprovisional filing date, subject to patent-term adjustment and any applicable pediatric extension. The patent was commercially relevant to generic Butrans litigation because an ANDA applicant could trigger a Paragraph IV dispute by alleging that the patent was invalid, unenforceable, or not infringed.

What triggered the Purdue Pharma v. Sandoz lawsuit?

Sandoz submitted an ANDA seeking FDA approval for a generic buprenorphine transdermal system. The filing included a Paragraph IV certification against one or more patents listed for Butrans.

Purdue's lawsuit followed the ANDA certification. Under the Hatch-Waxman framework, the filing of a patent infringement action within the statutory period generally creates a 30-month stay of FDA approval, subject to statutory exceptions and court action. The case therefore had two immediate commercial effects:

1. It delayed potential FDA approval of Sandoz's generic product.
2. It required Sandoz to defend the patentability and noninfringement positions stated in its ANDA.

The docket number, 1:12-cv-05082, identifies a 2012 filing in the Southern District of New York. The dispute was an ANDA-based patent action under the Drug Price Competition and Patent Term Restoration Act.

What were the main legal issues?

The central issues were the scope, validity, and enforceability of Purdue's transdermal buprenorphine patent rights.

Infringement

Purdue's infringement theory would have focused on whether Sandoz's proposed generic patch fell within the asserted claims. Relevant claim elements could include:

• Buprenorphine as the active pharmaceutical ingredient.
• A transdermal delivery system.
• The composition and arrangement of the drug-containing layer.
• Adhesive or matrix components.
• Release characteristics and dosage parameters.
• Use of the patch to deliver buprenorphine to a patient.

ANDA litigation evaluates the product described in the applicant's filing, not an already marketed generic product. The court therefore would have analyzed Sandoz's proposed product and technical specifications.

Validity

Sandoz's Paragraph IV defense could have challenged the asserted patent on grounds including:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Lack of written description.
• Lack of enablement.
• Indefiniteness under 35 U.S.C. § 112.

Transdermal drug-delivery patents often turn on claim construction, prior-art combinations, formulation predictability, and whether the claimed delivery profile was demonstrated across the full scope of the claims.

Enforceability

Sandoz also could have raised inequitable-conduct or other enforceability defenses. No publicly reported final decision in this action established that Purdue's patent was unenforceable.

How did the case end?

The action was resolved through settlement and dismissed. There is no widely reported opinion from the case that holds the asserted patent invalid, unenforceable, or not infringed.

The public record does not establish a judicial merits determination. As a result, the case should be classified as a settlement resolution rather than as precedent rejecting Purdue's Butrans patent estate.

Outcome question	Answer
Was there a reported jury verdict?	No
Was there a reported bench-trial judgment?	No
Was the patent invalidated in this action?	No public merits ruling established invalidity
Was noninfringement adjudicated?	No public merits ruling established noninfringement
Was the case dismissed?	Yes, after settlement
Were settlement terms fully public?	No

Settlement agreements in Hatch-Waxman cases may contain confidential commercial terms. Public dismissal records alone generally do not establish the agreed generic entry date, launch conditions, payment provisions, or licensing rights.

Did the settlement permit Sandoz to launch generic Butrans?

The case's dismissal does not, by itself, establish the date on which Sandoz could launch a generic buprenorphine patch. A settlement may provide for:

• A fixed generic entry date.
• An entry date tied to patent expiration.
• An authorized generic arrangement.
• A license limited to specified strengths or formulations.
• A launch contingent on regulatory approval.
• No commercial launch right if other patents remain blocking.

Without a publicly available and authenticated settlement agreement, the docket cannot be used to state a definitive Sandoz launch date or settlement economics.

Sandoz's practical launch risk also depended on patents not necessarily resolved in the case. Later-issued formulation patents, regulatory exclusivity, manufacturing patents, and separate litigation could have affected market entry.

What was the FDA and Orange Book status of Butrans?

Butrans was approved by the FDA as a buprenorphine transdermal system for chronic pain. FDA approval of the reference product did not eliminate patent barriers to generic approval.

The Orange Book identifies patents and exclusivity information submitted by the reference-product sponsor. For Butrans, the relevant patent landscape included transdermal buprenorphine patents, including U.S. Patent No. 7,074,430 and later patent rights associated with the product and its delivery system.

Regulatory timing

Regulatory event	Significance
Butrans FDA approval	Established the reference product for ANDA comparison
Sandoz ANDA filing	Created the Paragraph IV patent dispute
Purdue complaint	Triggered Hatch-Waxman litigation consequences
Settlement and dismissal	Ended the court action without a reported merits judgment
Generic approval	Depended on patent, exclusivity, and FDA conditions beyond the complaint alone

The 30-month stay generated by the patent suit was a regulatory constraint, not a final determination that the patent was valid. FDA approval could still be affected by patent expiration, settlement terms, statutory exceptions, or other Orange Book-listed patents.

How strong was Purdue's Butrans patent estate?

The estate had meaningful strategic value because it covered a specialized delivery system rather than only the active ingredient. Buprenorphine itself was a known opioid, but a transdermal patch required a commercially viable combination of drug loading, adhesive or matrix design, release control, skin permeation, stability, and manufacturability.

The estate's principal strengths were:

• Product-specific protection for transdermal delivery.
• A regulatory framework that permitted a Paragraph IV challenge to be litigated before generic approval.
• Potential coverage of patch formulations and delivery parameters.
• Commercial importance of the Butrans dosage form to Purdue's pain portfolio.

The principal vulnerabilities were:

• Prior art involving buprenorphine and transdermal opioid delivery.
• Obviousness arguments based on combining known opioid patch technologies.
• Claim-construction disputes over structural and functional limitations.
• Design-around opportunities involving adhesive systems, drug loading, or release profiles.
• The finite term of the patent portfolio.

Because the Sandoz case ended in settlement, it did not produce a court-tested assessment of the patent's validity or claim scope.

What generic entry risks existed for Butrans?

Generic entry risk was substantial once multiple ANDA applicants challenged the Butrans patent estate. The risk depended on the interaction of patent expiration, Paragraph IV certifications, litigation outcomes, settlement terms, and the number of competing generic applicants.

Main entry scenarios

Entry after patent expiration

A generic applicant could enter after expiration of the relevant blocking patent rights, subject to FDA approval and any remaining exclusivity.

At-risk launch

A company could launch before final resolution of patent litigation. This strategy carries exposure to damages, injunction risk, and potential market disruption if the patent holder later prevails.

Settlement-authorized entry

The settlement could establish a negotiated launch date or license. This was the most likely commercial mechanism for resolving the Purdue-Sandoz dispute, but the public case record does not establish its precise terms.

Entry after another applicant's challenge

A first-filer's Paragraph IV position can affect later applicants through 180-day generic exclusivity rules. The commercial impact depends on the ANDA filing sequence and the status of other applicants.

Which companies challenged Purdue's Butrans patents?

Purdue faced broader generic pressure around buprenorphine transdermal systems. Companies participating in related Butrans patent disputes or generic development included Sandoz and other ANDA sponsors, depending on the specific strength, filing date, and patent claims at issue.

The competitive landscape included:

• Sandoz, a major generic manufacturer and the defendant in this action.
• Other generic drug companies pursuing buprenorphine patches.
• Purdue and its affiliated entities as the reference-product sponsor and patent owner or exclusive rights holder.
• FDA as the regulator responsible for ANDA review and approval.

A separate lawsuit against another ANDA applicant should not be treated as part of this docket unless it involved the same patents, product, and claims.

What was the commercial significance of the litigation?

Butrans was a branded extended-release opioid product with a transdermal delivery profile. Generic entry could reduce prices and shift prescriptions to competing manufacturers. The value at risk included:

• Revenue from branded Butrans prescriptions.
• Prescriber retention in chronic-pain treatment.
• Pharmacy substitution after generic approval.
• Contracting leverage with payers and pharmacy-benefit managers.
• Manufacturing scale and supply reliability.

The precise revenue exposure attributable to Sandoz cannot be determined from the litigation docket. Market impact would have depended on the number of approved generic products, the settlement entry date, the availability of different strengths, and the commercial substitution rate.

How does this case compare with an OxyContin patent case?

Purdue Pharma v. Sandoz, No. 1:12-cv-05082, concerned a transdermal buprenorphine product, not OxyContin or an oxycodone extended-release formulation.

Issue	Butrans litigation	OxyContin litigation
Active ingredient	Buprenorphine	Oxycodone
Dosage form	Transdermal patch	Oral extended-release tablet
Core technology	Transdermal delivery	Controlled-release and abuse-deterrent formulation
Case at issue	1:12-cv-05082	Separate Purdue patent actions
Generic pathway	ANDA Paragraph IV	ANDA Paragraph IV
Resolution here	Settlement and dismissal	Must be analyzed by separate docket

Treating the case as an OxyContin dispute would produce an inaccurate patent and commercial analysis.

Key Takeaways

• Purdue sued Sandoz over an ANDA for a generic version of Butrans, a buprenorphine transdermal system.
• The case was filed in the Southern District of New York as No. 1:12-cv-05082.
• U.S. Patent No. 7,074,430 was the central patent associated with Purdue's transdermal buprenorphine technology.
• The dispute arose from a Paragraph IV certification under the Hatch-Waxman Act.
• The litigation ended by settlement and dismissal.
• No public merits judgment established that the asserted patent was invalid, unenforceable, or not infringed.
• The docket does not establish a definitive Sandoz launch date or the settlement's commercial terms.
• The case involved Butrans, not OxyContin.
• Later patents, FDA requirements, and separate litigation could affect generic entry independently of this action.

FAQs About Purdue Pharma v. Sandoz, No. 1:12-cv-05082

What was Sandoz's generic product in the Purdue Pharma lawsuit?

Sandoz pursued a generic buprenorphine transdermal system comparable to Purdue's Butrans product.

Was U.S. Patent No. 7,074,430 invalidated?

No. The case ended without a public merits decision invalidating the patent.

Did Purdue win the case against Sandoz?

The case did not produce a reported trial victory. It was resolved through settlement and dismissal.

Was the Purdue-Sandoz settlement a reverse-payment agreement?

The public docket does not establish the economic terms of the settlement or whether it included any payment arrangement.

Did this lawsuit determine when generic Butrans could launch?

No. The dismissal alone does not establish a generic launch date. Launch timing could depend on confidential settlement terms, patent expiration, FDA approval, and other listed patents.

References

1. U.S. District Court for the Southern District of New York. (2012). Purdue Pharma L.P. v. Sandoz Inc., No. 1:12-cv-05082.

2. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,074,430: Transdermal delivery of buprenorphine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.

4. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

5. Drug Price Competition and Patent Term Restoration Act, 35 U.S.C. § 271(e).